Latest trends in diabetes type one management

George Kebaso reports in Kenyan digital outlet, People Daily, on the Access to Medicine Foundation’s latest report, examining how pharmaceutical companies are working to improve access to essential diabetes care in low- and middle-income countries (LMICs), where many children and young people (CYP) still lack reliable access to life-saving products for type 1 diabetes (T1D).

The article, citing data from the Foundation’s new report, notes that without urgent action, global cases of type 1 diabetes (T1D) among children and young people (T1D) could reach 2.2 million by 2040, as access to insulin and essential care remains a major challenge in low- and middle-income countries (LMICs).

It highlights 11 pharmaceutical company-led initiatives aimed at supporting CYP with T1D, including efforts by Biocon, Lilly, Sanofi and Novo Nordisk. Despite these, the article stresses that coverage remains limited, and the vast majority of CYP in need continue to face significant barriers to accessing life-saving insulin and related care.

“Hundreds of thousands of children and young people in low- and middle-income countries face significant barriers to accessing essential insulin, supplies and care for managing type 1 diabetes,” the article quotes Claudia Martínez, Director of Research at the Access to Medicine Foundation. “As needs grow, initiatives must prioritise widespread coverage, sustainability and affordability to save lives.”